Cel Sci (CVM) Cash & Equivalents (2010 - 2026)
Cel Sci (CVM) posted Cash & Equivalents of $1.9 million for Q1 2026, down 69.88% sequentially from $6.3 million in Q4 2025, and down 1.74% YoY from $1.9 million in Q1 2025.
Cel Sci (CVM) Cash & Equivalents (2010 - 2026) Analysis & Trends
Cel Sci has reported Cash & Equivalents for 17 years, with the latest figure at $1.9 million in Q1 2026.
- Quarterly Cash & Equivalents fell 1.74% year-over-year to $1.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.9 million (down 1.74% YoY) and the FY2025 annual result came in at $11.0 million, up 131.17% from the prior year.
- Cash & Equivalents declined to $1.9 million in Q1 2026 per CVM's latest filing, from $6.3 million in the prior quarter.
- Over five years, Cash & Equivalents peaked at $34.3 million in Q1 2022 and troughed at $384652.0 in Q2 2024.
- A 5-year average of $9.6 million and a median of $5.1 million in 2023 frame the typical range for Cash & Equivalents.
- The sharpest annual moves came in 2022 and 2024: Cash & Equivalents soared 433.06% in 2022, then slumped 92.51% in 2024.
- Over 5 years, Cash & Equivalents stood at $18.0 million in 2022, then tumbled by 82.01% to $3.2 million in 2023, then jumped by 42.35% to $4.6 million in 2024, then soared by 36.05% to $6.3 million in 2025, then tumbled by 69.88% to $1.9 million in 2026.
- According to Business Quant data, Cash & Equivalents over the past three periods registered $1.9 million, $6.3 million, and $11.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 6.14 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.46 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 3.58 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 1.72 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.71 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 8.93 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 544.80 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 811.99 Mn |
| 10 | Cel Sci | 2.12 Mn | -4.42 Mn | - | 6.53 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.89 Mn |
| Dec 31, 2025 | 6.28 Mn |
| Sep 30, 2025 | 10.95 Mn |
| Jun 30, 2025 | 1.79 Mn |
| Mar 31, 2025 | 1.92 Mn |
| Dec 31, 2024 | 4.61 Mn |
| Sep 30, 2024 | 4.74 Mn |
| Jun 30, 2024 | 384,652.00 |
| Mar 31, 2024 | 5.31 Mn |
| Dec 31, 2023 | 3.24 Mn |
| Sep 30, 2023 | 4.15 Mn |
| Jun 30, 2023 | 5.14 Mn |
| Mar 31, 2023 | 10.05 Mn |
| Dec 31, 2022 | 18.02 Mn |
| Sep 30, 2022 | 22.67 Mn |
| Jun 30, 2022 | 28.07 Mn |
| Mar 31, 2022 | 34.28 Mn |
| Dec 31, 2021 | 37.11 Mn |
| Sep 30, 2021 | 36.06 Mn |
| Jun 30, 2021 | 35.96 Mn |